Results 131 to 140 of about 406,045 (339)

APOBEC-related mutagenesis and neo-peptide hydrophobicity: implications for response to immunotherapy. [PDF]

, 2019
Tumor-associated neo-antigens are mutated peptides that allow the immune system to recognize the affected cell as foreign. Cells carrying excessive mutation load often develop mechanisms of tolerance.
Boichard, Amélie, Frampton, Garrett M, Goodman, Aaron, Kurzrock, Razelle, Lippman, Scott, Pham, Timothy V, Tamayo, Pablo, Tsigelny, Igor F, Yeerna, Huwate   +8 more
core  

Common Signatures of Altered Gene Regulation and Invasiveness of Different Breast Cancer Cell Lines after Matrix Interface Crossing

Advanced Healthcare Materials, EarlyView.
Interface transmigration reprograms triple‐negative breast cancer cells, triggering a shared switch toward more aggressive and invasive phenotypes. Using a collagen I interface model, this study identifies shared transcriptional changes involving proliferation, chromatin remodeling, and DNA repair pathways.
Cornelia Clemens, Hannah Trampert, Nataliia Kotsiuba, Tilo Pompe   +3 more
wiley   +1 more source

CD-20-0047R2_Supplementary_Figure_2.pdf from Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade [PDF]

, 2023
Qu Zhang, Jia Luo, Song Wu, Han Si, Chen Gao, Wenjing Xu, Shaad E. Abdullah, Brandon W. Higgs, Phillip A. Dennis, Michiel S. van der Heijden, Neil H. Segal, Jamie E. Chaft, Todd Hembrough, J. Carl Barrett, Matthew D. Hellmann   +14 more
openalex   +1 more source

Immune checkpoint inhibitor-related endocrinopathies

Journal of Translational Internal Medicine, 2022
Lu, Difei, Gao, Ying
openaire   +2 more sources

Nanotherapies for Atherosclerosis: Targeting, Catalysis, and Energy Transduction

Advanced Healthcare Materials, EarlyView.
Atherosclerosis management is hindered by poor drug targeting and plaque heterogeneity. Nanotechnology overcomes these barriers via three core strategies: (1) target‐engineered nanocarriers that achieve lesion‐specific precision via ligand modification, biomimetic camouflage, stimuli‐responsive release, and self‐propelling nanomotors; (2) catalytic ...
Yuqi Yang, Jingguo Qu, Tonghuan Xiao, Xinyang Han, Michael Tin‐Cheung Ying   +4 more
wiley   +1 more source

Nanomaterials and immune checkpoint inhibitors in cancer immunotherapy: the synergistic innovation prospects

Frontiers in Immunology
Tumor cells can utilize the immune checkpoint pathway to inhibit T cell activation and evade the attack of tumor specific T cells. While immune checkpoint inhibitors (ICIs) competitively bind to checkpoint molecules to block checkpoint mediated ...
Jing Chen, Xue Cheng
doaj   +1 more source

948P Pre-treatment characteristics and long-term outcomes of recurrent-metastatic head and neck cancer patients treated with immune checkpoint inhibitors [PDF]

, 2020
Majd Issa, Thomas E Schultz, Menglin Xu, Priyanka Bhateja, Vidhya Karivedu, Khaled Dibs, Matthew Old, Stephen Y. Kang, Mauricio E. Gamez, J.C. Grecula, Sachin R. Jhawar, Darrion Mitchell, Nolan B. Seim, Amit Agrawal, E. Ozer, Sujith Baliga, Ricardo L. Carrau, James W. Rocco, Dukagjin Blakaj, Marcelo Bonomi   +19 more
openalex   +1 more source

Plant‐Produced Viral Nanoparticles Decorated with Nanobodies Against HER2 Improve Retention and Recruitment of Immune Cells in Solid Tumors

Advanced Healthcare Materials, EarlyView.
Potato virus X is a filamentous RNA plant virus that can be engineered into a molecular tool for cancer therapy. We produced genetically‐encoded virus‐derived nanoparticles decorated with nanobodies targeting cancer cell receptors, epidermal growth factor receptor (EGFR) and human epidermal growth factor 2 (HER2).
Enrique Lozano‐Sanchez, Miguel A. Moreno‐Gonzalez, Fernando Merwaiss, Nicole F. Steinmetz, José‐Antonio Daròs   +4 more
wiley   +1 more source

Anti–PD-1-induced bullous pemphigoid in a renal transplant recipient

SAGE Open Medical Case Reports
Immune checkpoint inhibitors, particularly anti–PD-1 agents, are increasingly associated with bullous pemphigoid, a rare yet significant immune-related adverse event. We report a case of immune checkpoint inhibitor-induced bullous pemphigoid in a 74-year-
Ghassan Barnawi, Abby Johanna Kpata, Raghad Aldibane, Sarah Kashkari, Raquel Lazarowitz, Manish Khanna   +5 more
doaj   +1 more source

Figure S5 from Immune-Checkpoint Blockade Opposes CD8⁺ T-cell Suppression in Human and Murine Cancer [PDF]

, 2023
Lukas W. Pfannenstiel, C. Marcela Díaz‐Montero, Ye F. Tian, Joseph Scharpf, Jennifer S. Ko, Brian Gastman   +5 more
openalex   +1 more source